In the PREDDICT study, participants with major depressive disorder (MDD) received anti-depressive vortioxine augmented with either Celecoxib or placebo in a randomised trial. We identified genomic variations of 24 pre-selected genes related to depression and immune response (e.g. CRP, TNFa) based on DNA whole-genome sequencing data of PREDDICT participants. Response to treatment in both therapy arms was linearly modelled in a multi modal approach, based on identified genetic variations and inflammatory blood marker levels. As a second aim, we also studied the effect of gene variations on change in inflammatory blood marker levels after anti-inflammatory treatment.
Title: Modelling therapy response to anti-inflammatory augmented treatment of depression based on DNA whole-genome sequencing data and inflammatory blood markers
Speaker: Toni Lange, Germany
Pharmacogenomics webinar series: Genetic and molecular factors play a pivotal role in determining psychiatric treatment response, shaping the future of precision medicine. The Pharmacogenomics webinar series is organised by the ECNP Pharmacogenomics and Transcriptomics Network.
This online series features leading experts discussing biosignatures for treatment (non-)response, optimising clinical trial strategies, and promoting the transfer of cutting-edge knowledge to improve patient outcomes.
By registering, you consent to the sharing of your e-mail address with the Pharmacogenomics webinar organisers.
